Citius Oncology, Inc.
CTOR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001851484
No open-market purchases or sales by Citius Oncology, Inc. insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $9.20M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Citius Oncology, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 16 | 18 | +2 |
| Shares | 8.36M | 6.86M | −1.50M (−17.9%) |
| Value | $17.0M | $6.86M | −$10.1M (−59.6%) |
New holders (6)
Institutions that held Citius Oncology, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Omers Administration Corp | 104,500 | $104.5K | 0.00% |
| Two Sigma Investments, LP | 23,515 | $23.5K | 0.00% |
| BlackRock, Inc. | 22,344 | $22.3K | 0.00% |
| Two Sigma Securities, LLC | 13,360 | $13.4K | 0.00% |
| Versant Capital Management, Inc | 1,500 | $1.50K | 0.00% |
| Royal Bank of Canada | 23 | $0 | 0.00% |
Sold out (4)
Institutions that held Citius Oncology, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Renaissance Technologies LLC | 55,900 | $113.5K |
| Citadel Advisors LLC | 17,661 | $35.9K |
| Tower Research Capital LLC (TRC) | 11,846 | $24.0K |
| Morgan Stanley | 5 | $10 |